Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.

The U.S. Food and Drug Administration regulatory body accepted for priority review the use of Sanofi and Regeneron’s Dupixent product for children aged 6-11 with moderate-to-severe eczema,

Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.

Paris-based Sanofi announced the inaugural opening of the company’s first new digital manufacturing facility for biologics production in Framingham, Massachusetts.

The U.S. Food and Drug Administration approved expanded use of Regeneron Pharmaceuticals Inc. and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17 years.

Sanofi will pay Regeneron about $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body’s own immune system fight cancer.

Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.

Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc.’s chief executive said after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter 2017 results.

On Sept. 11, 2017, Regeneron Pharmaceuticals and Sanofi announced positive data for its Phase III LIBERTY ASTHMA QUEST trial of Dupixent (dupilumab) in asthma. Investors and analysts do not seem to agree on whether dupilumab is on its way to being one of the biggest blockbuster drugs in the last two years, or if it’s the most overhyped drug on the market.

Regeneron Pharmaceuticals Inc.’s second-quarter 2017 profit handsomely beat estimates on strong demand for its flagship Eylea drug.